Imatinib‑induced gynecomastia: A case report

Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the unregulated and abnormal proliferation of both mature and immature granulocytes, which results in the proliferation of peripheral blood leukocytes. Imatinib, a tyrosine kinase inhibitor, is the first-line treatment for pa...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2024-11, Vol.28 (5), Article 425
Main Authors: Li, Xiao-Lan, Li, Min, Tu, Sheng-Ke, Fan, Hong-Jie, Shi, Zi-Wei, Wang, Ling-Zhi, Tian, Juan, Song, Kui
Format: Article
Language:English
Subjects:
Abdomen
Antimitotic agents
Antineoplastic agents
Blood
Bone marrow
Breast cancer
Cancer
Care and treatment
Case Report
Case reports
Case studies
Cell growth
Complications and side effects
Development and progression
Edema
Growth factors
Gynecomastia
Hepatitis B
Hormones, Sex
Hyperplasia
Kinases
Liver
Nilotinib
Older people
Oncology, Experimental
Outpatient care facilities
Pathogenesis
Patients
Pharmacology, Experimental
Physiological aspects
Risk factors
Testosterone
Thyroid gland
Tumors
Tyrosine
Ultrasonic imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the unregulated and abnormal proliferation of both mature and immature granulocytes, which results in the proliferation of peripheral blood leukocytes. Imatinib, a tyrosine kinase inhibitor, is the first-line treatment for patients diagnosed with chronic myeloid leukemia. However, despite its favorable safety profile, imatinib use is associated with a number of side effects. Gynecomastia is a rare adverse effect of imatinib treatment and may be associated with an imbalance in sex hormones. The present study reports the case of a patient with chronic myeloid leukemia diagnosed with gynecomastia after imatinib treatment. The aim of the present report was to highlight to clinicians this adverse reaction to imatinib treatment and investigate a treatment strategy with fewer side effects.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2024.12714